Owlstone Medical Secures Major ARPA-H Grant to Develop Breathalyzer for Early Cancer Detection
October 06, 2025
UK-based Owlstone Medical has been awarded up to 9.1 million by ARPA-H to develop cutting-edge breathalyzer technology aimed at early cancer detection. This funding is a significant step forward in leveraging innovation to tackle critical health challenges.